Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport.
Fresh hepatocytes cultured in a sandwich configuration allow for the development of intact bile canaliculi and the ability to measure hepatic uptake and biliary clearance. A disadvantage of this model is its dependence upon hepatocytes from fresh tissue. Therefore, the ability to use cryopreserved human hepatocytes in this model would be a great advantage. Multiple variables were tested, and the recommended conditions for culturing cryopreserved human hepatocytes in a sandwich configuration in 24-well plates are as follows: BioCoat plates, a cell density of 0.35 x 10(6) cells/well in 500 microl, an overlay of Matrigel and InVitroGRO media. These conditions resulted in good hepatocyte morphology and the formation of distinct bile canaliculi. The function of multiple uptake and efflux transporters was tested in multiple lots of cryopreserved and fresh human hepatocytes. For taurocholate [Na+ taurocholate cotransporting polypeptide/organic anion transporting polypeptide (OATP) uptake/bile salt export pump efflux], the average apparent uptake, apparent intrinsic biliary clearance, and biliary excretion index among five cryopreserved hepatocyte lots was high, ranging from 11 to 17 pmol/min/mg protein, 5.8 to 10 microl/min/mg protein, and 41 to 63%, respectively. The corresponding values for digoxin (OATP-8 uptake/multidrug resistance protein 1 efflux) were 0.69 to 1.5 pmol/min/mg protein, 0.60 to 1.5 microl/min/mg protein, and 37 to 63%. Both substrates exhibited similar results when fresh human hepatocytes were used. In addition, substrates of breast cancer resistance protein and multidrug resistance-associated protein 2 were also tested in this model, and all cryopreserved lots showed functional transport of these substrates. The use of cryopreserved human hepatocytes in 24-well sandwich culture to form intact bile canaliculi and to exhibit functional uptake and efflux transport has been successfully demonstrated.
Bi
Yi-an
YA
ADME Technology Group, Department of Pharmacokinetics, Dynamics & Metabolism, Groton/New London Laboratories, Pfizer, Inc., Groton, CT 06340, USA.
Kazolias
Diana
D
Duignan
David B
DB
D000293:Adolescent; D000368:Aged; D001648:Bile Canaliculi / Q000166:cytology / Q000378:metabolism*; D001692:Biological Transport; D018929:Cell Culture Techniques; D002478:Cells, Cultured; D002675:Child, Preschool; D015925:Cryopreservation; D004077:Digoxin / Q000378:metabolism; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004958:Estradiol / Q000031:analogs & derivatives / Q000378:metabolism; D005260:Female; D022781:Hepatocytes / Q000166:cytology / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D008297:Male; D026901:Membrane Transport Proteins / Q000378:metabolism; D008875:Middle Aged; D013656:Taurocholic Acid / Q000378:metabolism
D026901:Membrane Transport Proteins; C025483:estradiol-17 beta-glucuronide; D004958:Estradiol; D013656:Taurocholic Acid; D004077:Digoxin